Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-10

Study Completion Date

2020-01-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to compare the brain amyloid load in fully, partially and non remitting depressed elderly patients at 8 weeks of antidepressant therapy, by using PET with \[F18\]AV45.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Apathy in Late Life Depression: New Biomarkers Using Actimetry and Magnetic Resonance Imaging

NCT03807167

Depression

COMPLETED NA

Determining Changes in Brain Structure Associated With Symptoms of Late-life Depression

NCT00178087

Late-Life Depression

COMPLETED

Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)

NCT01528241

Depression

COMPLETED PHASE1

Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)

NCT03430869

Major Depressive Disorder

COMPLETED PHASE2

Brain Imaging in Depression

NCT00050700

Depression Bipolar Disorder

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main aim of this study is to assess the brain amyloid load in treated depressed elderly subjects using PET with \[F18\]AV45. The investigators hypothesize that the brain amyloid load will be higher in non or partially remitting depressed subjects treated with antidepressants than in fully remitting ones. An additional two years follow-up will allow comparing the brain amyloid load at baseline between those who will have evolved towards MCI or MA and those who will not, including ApoE genotype, the cognitive performances at baseline, the hippocampus volume as assessed by MRI, the type and profile of mood disorder (number of past episodes, age at first episode, vascular risk factor profile, response profile to antidepressants), as covariates.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Elderly Major Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

18FAV45

Group Type EXPERIMENTAL

18FAV45

Intervention Type DRUG

Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18FAV45

Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult 55 years or older
* Native language : french
* Study period \> 7 years
* Major depression defined on the DSM-IV criteria assessed by MINI and HDRS score of 10 or over
* Affiliation to the national health insurance system
* Signed informed consent

Exclusion Criteria

* History of alcoholism or drug addiction
* MMSE less than or equal to 17
* Major depression with psychotic features
* Depressive episode resistant, patient who received two different antidepressants well conducted without significant therapeutic response
* Any current or past episode of mania, schizophrenia or any other psychotic disorder
* Any past history of stroke or Parkinson's disease
* Any current significant unstable illness
* Any past diagnosis of Alzheimer's disease
* Any current treatment by AcethylCholinesterae inhibitor, memantine or antidepressant therapy.
* Contraindications to MRI in patients with:

1. Metallic foreign body eye.
2. Any implanted electronic medical irremovably (pacemaker, neurostimulator, cochlear implants ...)
3. Metal heart valve,
4. Vascular clips formerly located on cranial aneurysm.
* Contraindications to antidepressants
* History of progressive disease that can affect the central nervous system such as uncontrolled diabetes, blood pressure greater than or equal to 180/100; chronic lung disease with hypoxia, head trauma with loss of consciousness greater than or equal to 15 minutes; brain surgery, encephalitis, recently treated cancer (\<1 year), altered cerebral metabolism including subjects with stroke sequelae extended. Patients with lacunar stroke without thalamic or striatal may be included.

Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No